Bio-Rad Laboratories B 2025 Q2 Earnings Strong Performance with Net Income Swinging 114.7%

Bio-Rad Laboratories B (BIO.B) reported its fiscal 2025 Q2 earnings on Jul 31st, 2025. Bio-Rad Laboratories B exceeded market expectations with a notable turnaround in profitability, achieving an EPS of $11.67 for Q2 2025 compared to a loss of $76.26 per share in Q2 2024. Furthermore, the company raised its full-year 2025 financial outlook, now anticipating non-GAAP, currency-neutral revenue growth between 0 to 1%, an upgrade from the prior forecast of a decline up to 1.5%. This adjustment reflects Bio-Rad's strategic execution and confidence in its growth prospects.

Revenue

Bio-Rad Laboratories B saw a total revenue increase of 2.1% in Q2 2025, reaching $651.60 million, up from $638.50 million in the same quarter of the previous year. The Life Science segment contributed $262.80 million, driven by heightened demand for process chromatography and food safety products, while Clinical Diagnostics remained stable at $388.80 million, despite reduced reimbursements in China.

Earnings/Net Income

Bio-Rad Laboratories B returned to profitability with an impressive EPS of $11.67 in Q2 2025, reversing from a substantial loss of $76.26 per share in Q2 2024. The company achieved a remarkable net income of $317.80 million, representing a 114.7% positive swing from the previous year's net loss of $-2.17 billion. This EPS reflects a strong recovery for the company.

Price Action

The stock price of Bio-Rad Laboratories B edged down 0.00% during the latest trading day, remained unchanged over the most recent full trading week, and decreased by 1.21% month-to-date.

Post-Earnings Price Action Review

The investment strategy of purchasing Bio-Rad Laboratories B (BIO.B) shares after a quarter-over-quarter revenue increase on the earnings release date and holding for 30 days has underperformed significantly over the past three years. This approach resulted in an 85.57% underperformance compared to the benchmark, with a compound annual growth rate stagnant at 0.00% and no excess return. Additionally, the strategy exhibited a maximum drawdown of 0.00% and volatility of 0.00%, demonstrating a lack of risk-adjusted returns and absence of capital appreciation. Despite the substantial revenue increase reported, the stock failed to yield tangible gains within the specified timeframe, highlighting the importance of considering broader market dynamics and long-term strategic goals when evaluating stock purchase strategies.

CEO Commentary

Norman Schwartz, Chairman and CEO of Bio-Rad Laboratories, emphasized the company's solid quarterly results amid a dynamic environment, noting a 2.1% revenue increase driven by focused execution and careful expense management. He highlighted the successful acquisition of Stilla Technologies, enhancing the Droplet Digital™ PCR offering with the QX Continuum™ system. Despite challenges in the Clinical Diagnostics segment, particularly in diabetes testing reimbursements in China, Schwartz expressed confidence in strategic priorities, including investments in innovative technologies and expanding product offerings. This reflects an optimistic outlook for future growth.

Guidance

Bio-Rad Laboratories has updated its full-year 2025 financial outlook, now expecting non-GAAP, currency-neutral revenue growth of approximately 0 to 1.0%, an improvement from the previous range of a 1.0% decline to 1.5% growth. Additionally, the company estimates the non-GAAP operating margin to be approximately 12.0 to 13.0%, up from the earlier expectation of 10.0 to 12.0%.

Additional News

Bio-Rad Laboratories recently completed the strategic acquisition of Stilla Technologies, expanding its Droplet Digital PCR offerings with the launch of the QX Continuum™ system and QX700™ series platforms. This acquisition enhances Bio-Rad’s leadership in digital PCR solutions, strengthening its presence in genomics research and applied science markets. Additionally, the company introduced new bioanalytical antibodies and reagents, enhancing its range for antibody drug development and bioanalysis. Bio-Rad also launched the XP-Design Assay Salmonella Serotyping Solution, aimed at rapid and accurate food safety testing, showcasing its commitment to innovative solutions across diverse scientific applications.